The Gavriel Meir Trust Adds $450,000 to Extend Existing Collaboration between Charley’s Fund/Nash Avery Foundation and CombinatoRx, Incorporated to Continue Developing Novel Agents for Duchenne Muscular Dystrophy

SOUTH EGREMONT, Mass.--(BUSINESS WIRE)--Charley’s Fund, Nash Avery Foundation and The Gavriel Meir Trust all non-profit organizations founded to support Duchenne muscular dystrophy (DMD) research, today announced an extension to the existing collaborative agreement between CombinatoRx, Incorporated, Charley’s Fund and the Nash Avery Foundation to identify novel disease-modifying multi-targeted treatments for DMD, the most common form of muscular dystrophy.